Wedbush Maintains Outperform on Climb Bio, Raises Price Target to $27
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Wedbush analyst Laura Chico maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $25 to $27.
Wedbush analyst Laura Chico maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $25 to $27.